As­traZeneca builds in­to Chi­na; Eli Lil­ly hit with 483; GSK’s new col­lab­o­ra­tion 

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

As­traZeneca and Taizhou Na­tion­al Med­ical High-tech De­vel­op­ment Zone have part­nered to ex­pand the Big Phar­ma’s pres­ence in Chi­na, As­traZeneca con­firmed to End­points News. The com­pa­ny will be in­vest­ing 190 mil­lion yuan ($26.8 mil­lion) to build a new pro­duc­tion line for met­formin hy­drochlo­ride and the di­a­betes ther­a­py Da­pagliflozin, as first re­port­ed by Chi­na Dai­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER